Advertisement
Advertisement

BCRX

BCRX logo

BioCryst Pharmaceuticals Inc

8.70
USD
Sponsored
+0.20
+2.35%
Jun 12, 16:00 UTC -4
Closed
exchange

After-Market

8.76

+0.06
+0.63%

BCRX Earnings Reports

Positive Surprise Ratio

BCRX beat 22 of 42 last estimates.

52%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$188.59M
/
$0.14
Implied change from Q1 26 (Revenue/ EPS)
+20.57%
/
-255.56%
Implied change from Q2 25 (Revenue/ EPS)
+15.45%
/
+250.00%

BioCryst Pharmaceuticals Inc earnings per share and revenue

On May 06, 2026, BCRX reported earnings of -0.09 USD per share (EPS) for Q1 26, missing the estimate of 0.04 USD, resulting in a -281.82% surprise. Revenue reached 156.41 million, compared to an expected 154.15 million, with a 1.47% difference. The market reacted with a -2.21% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.14 USD, with revenue projected to reach 188.59 million USD, implying an decrease of -255.56% EPS, and increase of 20.57% in Revenue from the last quarter.
FAQ
For Q1 2026, BioCryst Pharmaceuticals Inc reported EPS of -$0.09, missing estimates by -281.82%, and revenue of $156.41M, 1.47% above expectations.
The stock price moved down -2.21%, changed from $9.03 before the earnings release to $8.83 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 6 analysts, BioCryst Pharmaceuticals Inc is expected to report EPS of $0.14 and revenue of $188.59M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement